The Use of Imiquimod in the Treatment of Periocular Tumours

Bristol Eye Hospital, Lower Maudlin Street, Bristol, UK.
Orbit (Amsterdam, Netherlands) 04/2010; 29(2):83-7. DOI: 10.3109/01676830903294909
Source: PubMed


To review our experience with 5% topical Imiquimod in the treatment of periocular tumours.
Imiquimod, an imidazoquinoline, is an immune response modifier which has been shown to have potent anti-viral and anti-tumour activity. We present a retrospective case series of 5 patients who received topical Imiquimod for various eyelid tumours. Two patients were diagnosed with basal cell carcinoma of the eyelid, one patient with actinic keratosis, one with intraepidermal squamous cell carcinoma (Bowen's disease) and one patient had concomitant squamous cell carcinoma and intraepidermal squamous cell carcinoma.
All 5 patients, with various eyelid neoplastic/pre-neoplastic pathology, responded well with clinical resolution, to treatment with topical Imiquimod. There were few adverse reactions to periocular use of 5% Imiquimod, with only 1 patient developing a chemical conjunctivitis which resolved on dose reduction.
There is limited experience and published literature on the use of topical 5% Imiquimod in the treatment of periocular tumours. In our experience, it is a safe and effective treatment for periocular lesions, including actinic keratosis, intraepidermal squamous cell carcinoma, basal cell carcinoma and squamous cell carcinoma. To our knowledge, this is the first published description of the successful use of 5% Imiquimod in treating moderately differentiated squamous cell carcinoma of the eyelid.

3 Reads
  • Source
    • "Minimally invasive treatments are being considered, mostly because BCC shows less possibility of malignancy and to avoid great tissue loss in the facial region. PDT in BCC mostly requires application of methyl aminolevulinate cream over tumor lesions and surrounding tissues, and leads to better esthetic results and a better treatment rate [51] [62] [70]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Photodynamic therapy (PDT) is a special type of treatment involving the use of a photosensitizer or a photosensitizing agent along with a special type of light, which, combined together, induces production of a form of oxygen that is used to kill surrounding cells in different areas of the human body. Specification of the head and neck region requires different approaches due to the surrounding of vital structures. PDT can also be used to treat cells invaded with infections such as fungi, bacteria and viruses. The light beam placed in tumor sites activates locally applied drugs and kills the cancer cells. Many studies are taking place in order to invent better photosensitizers, working on a larger scale and to treat deeply placed and larger tumors. It seems that PDT could be used as an alternative surgical treatment in some tumor types; however, all clinicians should be aware that the surgical approach is still the treatment of choice. PDT is a very accurate and effective therapy, especially in early stages of head and neck squamous cell carcinomas (HNSCC), and can greatly affect surgical outcomes in cancerous patients. We present a detailed review about photosensitizers, their use, and therapeutic advantages and disadvantages.
    Postępy Higieny i Medycyny Doświadczalnej (Advances in Hygiene and Experimental Medicine) 01/2014; 68:119-28. DOI:10.5604/17322693.1088044 · 0.57 Impact Factor

  • Archivos de la Sociedad Espanola de Oftalmologia 08/2010; 85(8):261-2. DOI:10.1016/S2173-5794(10)70043-8

  • Fuel and Energy Abstracts 08/2010; 85(8):261-262. DOI:10.1016/j.oftal.2010.09.008
Show more